SCL Healthcare Develops Platelet RNA-Based Multi-Cancer Early Detection AI Technology... Selected for Gyeonggi Province Research Project View original image

SCL Healthcare is embarking on the development of next-generation multi-cancer early detection (MCED) technology utilizing platelet RNA. The company announced on June 10 that it was recently selected as the final executing agency for the Gyeonggi Province Technology Development Project, which is overseen by the Gyeonggi Institute of Science & Technology Promotion.


The project selected this time is titled "Development of MCED AI Screening Technology Using Genomics." For the research and development, SCL Healthcare will receive research funding from the Gyeonggi Institute of Science & Technology Promotion.


The multi-cancer early detection technology under development by SCL Healthcare is a next-generation liquid biopsy-based platform that combines bioinformatics with deep learning technology. With a single blood draw, platelets are extracted from the blood, and then the genomic signals inside the platelets are precisely analyzed to simultaneously predict both the presence of cancer and the type of cancer.


This technology is particularly notable for leveraging the RNA information of platelets, which interact closely with cancer cells. The AI model is designed to learn and analyze genomic data obtained from platelets, enabling the early screening of multiple cancer types.


According to SCL Healthcare, the model demonstrated cancer detection accuracy of over 91% for 13 cancer types in a preliminary evaluation using samples from more than 2,000 individuals. The company also explained that the accuracy for predicting cancer types averaged around 70%.


Notably, while conventional circulating tumor DNA (ctDNA)-based MCED technologies have shown relatively low diagnostic accuracy in the early stages of cancer, SCL Healthcare emphasized that its platelet-based model achieved early detection accuracy of over 84% on average in stage 1 and stage 2 early cancers.


A company spokesperson stated, "Through this Gyeonggi Province support project, we plan to further enhance our AI technology for cancer detection and tumor type prediction, as well as increase the reliability of our validation data," adding, "We are currently filing for domestic patents and will also pursue overseas patents as soon as possible."


The spokesperson further added, "We aim to present our results in international academic journals and commercialize this as an actual health screening product, thereby providing high-quality multi-cancer early detection services."


The liquid biopsy-based cancer diagnosis market is currently valued at about 250 billion won annually, and it is expected to grow at an average annual rate of approximately 10% until 2035. Recently, as companies with liquid biopsy-based MCED technology have been recognized with high valuations in the Korean stock market, expectations for the related market are rising.


SCL Healthcare is a subsidiary of SCL Science, which is responsible for data-driven precision medicine within the SCL Group. The company develops and provides genetic testing and companion diagnostics services, and also operates central lab services. Recently, it has expanded its R&D activities by announcing companion diagnostics technology for ovarian cancer and Korean-type metabolic disease testing technology.


In addition, SCL Science is accelerating research and business development in the field of precision medicine based on its "single-cell big data warehouse," which strengthens its cell-level data analysis capabilities.


Meanwhile, SCL Group operates a variety of healthcare affiliates, including Seoul Clinical Laboratories (SCL), Hanaro Medical Foundation, SCL Science, Mediinfra, Qlogic, Biofood Lab, and Holmes AI.



SCL Healthcare plans to actively target the next-generation multi-cancer early detection market, leveraging its platelet RNA-based liquid biopsy technology and AI analysis capabilities.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing